Multi-Industry Comments on the Voluntary Disclosure of Sesame as an Allergen
ASTA signed onto industry coalition comments to the Food and Drug Administration (FDA) in February 2021 regarding the FDA's draft guidance titled Voluntary Disclosure of Sesame as an Allergen.
02/25/2021 at 5:15 am
1
Related Resources
ASTA Comments to FDA on Voluntary Sesame Labeling Guidance
ASTA issued comments to the Food and Drug Administration (FDA) in February 2021 on the Voluntary Disclosure of Sesame as an Allergen: Guidance for Industry. Comments outline inconsistencies and confusion arising from the guidance, including that FDA policy already provides that sesame should not be labeled under the generic declaration of spices. ASTA requests that FDA revoke the voluntary guidance due to the legislative process and the FASTER Act.
Coalition Comments to FDA Requesting Sesame Labeling Compliance Date Clarification
ASTA signed onto FBIA coalition comments to the Food and Drug Administration (FDA) in April 2022, requesting that the FDA clarify that the compliance date under the Food Allergy Safety, Treatment, Education, and Research Act (FASTER) means that food products containing sesame must be labeled with a sesame allergen statement on or after January 1, 2021 and that products labeled before that do not need to be in compliance with the FASTER Act.
